Anti-inflammatory properties of marine lipid compositions

Patent metadata

Field	Value
Publication number	US-10525068-B2
Application number	US-201816180564-A
Country	US
Kind code	B2
Filing date	Nov 5, 2018
Priority date	May 5, 2006
Publication date	Jan 7, 2020
Grant date	Jan 7, 2020

Abstract

Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines.

First claim

The invention claimed is:

1. A gel capsule containing a lipid composition comprising a mixture of phospholipid molecules, having the following general structure:

wherein R1 and R2 are a fatty acid residue or —OH and R1 and R2 are not simultaneously —OH and R3 is a choline, ethanolamine, serine or inositol group and said mixture of phospholipid molecules is characterized in comprising at least 1% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2, said lipid composition has a lysophospholipid content of from 15% to 60% w/w of said composition, and said composition comprises triglycerides.

2. The gel capsule of claim 1 , wherein said lipid composition has a lysophospholipid content of from 15% to 30% w/w of said composition.

3. The gel capsule of claim 1 wherein said mixture of phospholipids has a ratio of EPA/DHA residues ranging from 1:1 to 4:1.

4. The gel capsule of claim 1 , wherein said mixture of phospholipids having a ratio of EPA/DHA residues ranging from 2:1 to 4:1.

5. The gel capsule of claim 1 , wherein said mixture of phospholipid molecules is characterized in comprising at least 15% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2.

6. The gel capsule of claim 1 , wherein said mixture of phospholipid molecules is characterized in comprising at least 20% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2.

7. A gel capsule containing a lipid composition comprising a mixture of phospholipid molecules, having the following general structure:

wherein R1 and R2 are a fatty acid residue or —OH and R1 and R2 are not simultaneously —OH and R3 is a choline, ethanolamine, serine or inositol group and said mixture of phospholipid molecules is characterized in comprising at least 15% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2, said lipid composition has a lysophospholipid content of from 15% to 60% w/w of said composition, and said composition comprises triglycerides.

8. The gel capsule of claim 7 , wherein said lipid composition has a lysophospholipid content of from 15% to 30% w/w of said composition.

9. The gel capsule of claim 7 , wherein said mixture of phospholipid molecules has a ratio of EPA/DHA residues ranging from 1:1 to 4:1.

10. The gel capsule of claim 7 , wherein said mixture of phospholipids having a ratio of EPA/DHA residues ranging from 2:1 to 4:1.

11. A gel capsule containing a lipid composition comprising a mixture of phospholipid molecules, having the following general structure:

wherein R1 and R2 are a fatty acid residue or —OH and R1 and R2 are not simultaneously —OH and R3 is a choline, ethanolamine, serine or inositol group and said mixture of phospholipid molecules is characterized in comprising at least 15% docosahexaenoic acid (DHA) residues or eicosapentaenoic acid (EPA) residues at positions R1 or R2 and said lipid composition has a lysophospholipid content of from 15% to 30% w/w of said composition.

12. The gel capsule of claim 11 , wherein said mixture of phospholipids has a ratio of EPA/DHA residues ranging from 1:1 to 4:1.

13. The gel capsule of claim 11 , wherein said mixture of phospholipids having a ratio of EPA/DHA ranging from 2:1 to 4:1.

14. The gel capsule of claim 11 , wherein said lipid composition further comprises triglycerides.

Assignees

• Aker Biomarine Antarctic As

Inventors

• Bruheim Inge
• Griinari Mikko
• Banni Sebastiano
• Saebo Per Christian
• Fuglseth Erik

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• C07F9/10

  Phosphatides, e.g. lecithin · CPC title

• A61K31/685 Primary

  one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin · CPC title